The PEI BioAlliance: How Canada’s Smallest Province is Leading Bioscience Innovation WHEN ONE THINKS OF PRINCE EDWARD ISLAND, images of rolling potato fields, fresh lobster, and red-headed orphans often come to mind. However, beneath the surface of these traditional industries, a thriving and rapidly expanding bioscience sector is transforming the Island into a global player in innovation. Bioscience is now PEI’s second-largest industry and its growth is nothing short of remarkable. Over the years, the PEI BioAlliance has nurtured a bioscience cluster that includes more than 60 companies and generates over $600 million in annual sales. In the last year, there were five billion-dollar bioscience transactions in Canada. Two of these deals happened in PEI—a testament to the province’s growing influence and capability in this sector. THE RISE OF A BIOSCIENCE POWERHOUSE Founded in 2005, the PEI BioAlliance is the ‘innovation intermediary’ of the Island’s bioscience cluster, catalyzing collaboration among private sector companies, investors, research institutions, and government agencies. The BioAlliance has played a pivotal role in aligning strategy, attracting investment, and accelerating the commercialization of scientific research. Today, PEI’s bioscience companies are leaders in human, animal, and fish health, natural product chemistry, and diagnostics. Recent initiatives like BIOVECTRA’s first-inCanada mRNA vaccine manufacturing facility, the development of the Canadian Alliance for Skills and Training in Life Sciences (CASTL), the Biomanufacturing Incubator, and the BioAccelerator are just a few examples of the exciting projects defining the province as a centre of expertise in biomanufacturing and driving the sector’s growth.
BILLION-DOLLAR DEALS AND EXPANDING HORIZONS PEI’s bioscience sector recently captured international headlines with two landmark transactions. In September 2024, Agilent Technologies completed its acquisition of PEI-based pharmaceutical company BIOVECTRA for $925 million (USD). In February 2024, Merck Animal Health acquired Elanco Animal Health’s aqua business for $1.3 billion in cash with PEI fish vaccine manufacturing assets a key part of the transaction. These landmark deals point to the broader trend of bioscience becoming a driver of economic prosperity in PEI. FROM COLLABORATION TO COMMERCIALIZATION What sets the BioAlliance apart is the unique collaboration between industry, government, research, and academic institutions. Through partnerships with the University of Prince Edward Island, Holland College, and the National Research Council’s Charlottetown-based Aquatic and Crop Resource Development labs, the PEI BioAlliance helps translate academic research into commercially viable products. Beyond billion-dollar deals, the BioAlliance is dedicated to attracting and supporting local, and global startups and SMEs whose technologies are a fit with cluster expertise and infrastructure offerings. Another key BioAlliance asset in this mission is Emergence, Atlantic Canada’s Bioscience Business Incubator, with over 50 clients across the region and beyond. NO ‘SMALL POTATOES’ With its expertise, infrastructure, talent, and collaborative spirit, PEI’s thriving bioscience sector proves that a small province can make a big impact, leading the way into a new era of prosperity and global recognition. The second-largest industry on the Island is redefining what is possible in economic diversification, positioning it as a leader in global bioscience innovation.
74
Fall | Automne 2024
BIOTECanada